MX378668B - Profarmacos y moduladores de receptores nmda, sales y usos de estos. - Google Patents

Profarmacos y moduladores de receptores nmda, sales y usos de estos.

Info

Publication number
MX378668B
MX378668B MX2016005510A MX2016005510A MX378668B MX 378668 B MX378668 B MX 378668B MX 2016005510 A MX2016005510 A MX 2016005510A MX 2016005510 A MX2016005510 A MX 2016005510A MX 378668 B MX378668 B MX 378668B
Authority
MX
Mexico
Prior art keywords
compounds
prodrugs
modulators
salts
nmda receptor
Prior art date
Application number
MX2016005510A
Other languages
English (en)
Other versions
MX2016005510A (es
Inventor
M Amin Khan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MX2016005510A publication Critical patent/MX2016005510A/es
Publication of MX378668B publication Critical patent/MX378668B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen los compuestos que tienen potencia mejorada en la modulación de la actividad del receptor NMDA. Se contemplan dichos compuestos para su uso en el tratamiento de enfermedades y trastornos, tales como trastornos de aprendizaje, actividades cognitivas y analgesia, particularmente en el alivio y/o reducción de dolor neuropático. También se describen las formulaciones disponibles oralmente y otras formas de administración farmacéuticamente aceptables de los compuestos, que incluyen formulaciones intravenosas.
MX2016005510A 2013-10-28 2014-10-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos. MX378668B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896308P 2013-10-28 2013-10-28
PCT/US2014/062367 WO2015065891A1 (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Publications (2)

Publication Number Publication Date
MX2016005510A MX2016005510A (es) 2017-01-06
MX378668B true MX378668B (es) 2025-03-10

Family

ID=53004986

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005510A MX378668B (es) 2013-10-28 2014-10-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos.
MX2021000029A MX2021000029A (es) 2013-10-28 2016-04-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000029A MX2021000029A (es) 2013-10-28 2016-04-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos.

Country Status (15)

Country Link
US (2) US9745342B2 (es)
EP (2) EP3062810A4 (es)
JP (1) JP6603668B2 (es)
KR (1) KR20160077153A (es)
CN (2) CN105764522A (es)
AU (2) AU2014342624A1 (es)
BR (1) BR112016009443A8 (es)
CA (1) CA2928701A1 (es)
CL (2) CL2016001001A1 (es)
IL (1) IL245302B (es)
MX (2) MX378668B (es)
RU (1) RU2016119830A (es)
SA (1) SA516371037B1 (es)
SG (2) SG11201603376UA (es)
WO (1) WO2015065891A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
BR112019002730A2 (pt) * 2016-08-11 2019-05-14 Intrabio Ltd acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
CN116082461B (zh) * 2022-10-14 2023-11-14 浙江大学 一种具有抗菌活性的小分子肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006030840A1 (ja) * 2004-09-14 2008-05-15 独立行政法人産業技術総合研究所 ムチン型ペプチドの合成法とｍｕｃ１関連糖ペプチド
US7960506B2 (en) * 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
WO2008104000A2 (en) * 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR101769999B1 (ko) * 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
JP2012503025A (ja) * 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド 精製されたポリペプチド組成物を調製するための方法
CA2789331C (en) * 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG194230A1 (en) * 2011-04-27 2013-12-30 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Also Published As

Publication number Publication date
MX2021000029A (es) 2021-03-25
EP3062810A4 (en) 2017-05-03
US20180127466A1 (en) 2018-05-10
AU2020201109A1 (en) 2020-03-05
RU2016119830A (ru) 2017-12-04
CN105764522A (zh) 2016-07-13
SA516371037B1 (ar) 2018-05-16
CN112321678A (zh) 2021-02-05
CA2928701A1 (en) 2015-05-07
US20160244485A1 (en) 2016-08-25
KR20160077153A (ko) 2016-07-01
CL2020002247A1 (es) 2021-02-05
WO2015065891A1 (en) 2015-05-07
IL245302A0 (en) 2016-06-30
IL245302B (en) 2020-05-31
BR112016009443A8 (pt) 2020-03-24
EP3062810A1 (en) 2016-09-07
SG10201810496XA (en) 2018-12-28
JP6603668B2 (ja) 2019-11-06
RU2016119830A3 (es) 2018-07-02
US9745342B2 (en) 2017-08-29
US10590167B2 (en) 2020-03-17
CL2016001001A1 (es) 2016-12-16
AU2014342624A1 (en) 2016-06-02
EP3564256A1 (en) 2019-11-06
JP2016537413A (ja) 2016-12-01
MX2016005510A (es) 2017-01-06
SG11201603376UA (en) 2016-05-30

Similar Documents

Publication Publication Date Title
PH12015501601A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
BR112014009851A8 (pt) moduladores de receptor de nmda e usos dos mesmos
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
EP2542254A4 (en) THROUGH A SECONDARY STRUCTURE STABILIZED RECEPTOR MODULATORS AND APPLICATIONS THEREOF
IN2014DN09434A (es)
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
GEP20207082B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
UA109260C2 (uk) Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX378668B (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018002786A (es) Composicion farmaceutica de vinpocetina.